- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders' interest, augment business development opportunities and positioning in the capital markets - PITTSBURGH, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today announced that it has entered into a binding letter of intent with Renovaro, Inc. (NASDAQ: ...

PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction. The transaction is expected to close on or about July 26, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transaction, coupled with an additional $3.58 million in net proceeds raised in May 2024 through the Company's at-the-market facility, for working capital and other general corporate purposes. This press release does not constitute an offer to sell or ...

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common ...

GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis. It is estimated that drugs targeting GPCRs represent more than 30% of the global market for therapeutic drugs, yet the number of characterized GPCR targets represent just a small fraction of the GPCR superfamily, suggesting significant potential to further target GPCRs for future drug discovery and development2,3. "As ...

Predictive Oncology's organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture market is projected to grow by more than 14% annually, from $1.4 billion in 2022 to nearly $5.3 billion annually by 20321 PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery a ...

Predictive Oncology's organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture market is projected to grow by more than 14% annually, from $1.4 billion in 2022 to nearly $5.3 billion annually by 20321 PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery a ...

PITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il. The purpose of the study was to determine if Predictive Oncology could lever ...

Predictive Oncology Inc. (NASDAQ:POAI) Q1 2024 Earnings Call Transcript May 15, 2024 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Operator Ladies and gentlemen, good morning, and thank you for standing by. Welcome to the Predictive Oncology Q1 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be an opportunity to ask your questions. Please be advised that today's co ...

EXHIBIT 99.1 Announced that an abstract detailing results of the recent study that Predictive Oncology completed in collaboration with UPMC Magee-Womens Hospital in Pittsburgh, PA, has been accepted as a poster presentation at the American Society for Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4 in Chicago. The study utilized multi-omic machine learning models to identify molecular features that better correlate to short- and long-term survival outcomes among women diagnosed wi ...